Dabrafenib and Trametinib for BRAF V600E-Positive Anaplastic Thyroid Cancer
Learn how dabrafenib and trametinib are used for BRAF V600E-positive anaplastic thyroid cancer, including response rates, survival, tumour shrinkage, conversion from inoperable to operable disease, side effects, resistance, surgery, radiation, and what patients should discuss with their treatment team.